Potential of triazines in Alzheimer's disease: A versatile privileged scaffold

Abstract Triazines are six‐membered privileged scaffolds that have been explored in drug discovery programs owing to their stability in biological media and robust reactivity. Their unique chemical properties have led to the exploration of the triazine‐containing molecules for multifaceted disorders like Alzheimer's disease (AD). The pathology of AD involves the interplay of multiple biochemical events such as amyloid beta‐aggregation, formation of reactive oxygen species, cholinergic degradation, and metal ion dysregulation. The growing incidence of AD, coupled with the limited availability of efficacious medicines, necessitates the identification of newer therapeutic approaches. Privileged scaffolds like triazines with the potential for multiple biological effects offer excellent alternatives to the treatment of multifactorial AD. The present review describes numerous triazine‐containing molecules capable of modulating single as well as multiple pathological factors involved in AD. The analysis of structural features of these molecules can provide useful insights for developing newer therapies.